Clinical trial
Evaluation of an Altered Peptide Ligand (NBI-5788) in Patients With Relapsing…
NCT00079495 · Neurocrine Biosciences, Industry · Completed
Key facts
| NCT number | NCT00079495 |
|---|---|
| Title | Evaluation of an Altered Peptide Ligand (NBI-5788) in Patients With Relapsing Multiple Sclerosis (MS) |
| Official title | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of NBI-5788 in Patients With Relapsing Multiple Sclerosis |
| Lead sponsor | Neurocrine Biosciences, Industry |
| Collaborators | Immune Tolerance Network (ITN) |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Sclerosis |
| Intervention type | Drug |
| Interventions | NBI-5788 |
| Enrollment | 150 |
| Start date | Jul 1, 2003 |
| Completion | Apr 1, 2005 |
| First posted | Mar 10, 2004 |
| Last update posted | Mar 21, 2008 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: